NASDAQ:BMRN BioMarin Pharmaceutical (BMRN) Stock Price, News & Analysis → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free bmrn Stock Alerts $80.91 -1.26 (-1.53%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$80.90▼$83.0950-Day Range$80.91▼$92.2252-Week Range$76.02▼$99.56Volume2.26 million shsAverage Volume1.70 million shsMarket Capitalization$15.27 billionP/E Ratio75.62Dividend YieldN/APrice Target$107.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get BioMarin Pharmaceutical alerts: Email Address BioMarin Pharmaceutical MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.63 Rating ScoreUpside/Downside32.9% Upside$107.50 Price TargetShort InterestHealthy1.96% of Shares Sold ShortDividend StrengthN/ASustainability-2.93Upright™ Environmental ScoreNews Sentiment0.39Based on 48 Articles This WeekInsider TradingSelling Shares$9.06 M Sold Last QuarterProj. Earnings Growth45.41%From $1.85 to $2.69 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.90 out of 5 starsMedical Sector21st out of 914 stocksBiotechnology Industry1st out of 22 stocks 4.3 Analyst's Opinion Consensus RatingBioMarin Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on 12 buy ratings, 7 hold ratings, and no sell ratings.Amount of Analyst CoverageBioMarin Pharmaceutical has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.96% of the outstanding shares of BioMarin Pharmaceutical have been sold short.Short Interest Ratio / Days to CoverBioMarin Pharmaceutical has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioMarin Pharmaceutical has recently increased by 20.59%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBioMarin Pharmaceutical does not currently pay a dividend.Dividend GrowthBioMarin Pharmaceutical does not have a long track record of dividend growth. Previous Next 3.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreBioMarin Pharmaceutical has received a 35.96% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Galsulfase", "Laronidase", and "Cerliponase alfa" products. See details.Environmental SustainabilityThe Environmental Impact score for BioMarin Pharmaceutical is -2.93. Previous Next 1.9 News and Social Media Coverage News SentimentBioMarin Pharmaceutical has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 48 news articles for BioMarin Pharmaceutical this week, compared to 7 articles on an average week.Search InterestOnly 8 people have searched for BMRN on MarketBeat in the last 30 days. This is a decrease of -53% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added BioMarin Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is a decrease of -64% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioMarin Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,062,967.00 in company stock.Percentage Held by InsidersOnly 1.84% of the stock of BioMarin Pharmaceutical is held by insiders.Percentage Held by Institutions98.71% of the stock of BioMarin Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for BioMarin Pharmaceutical are expected to grow by 45.41% in the coming year, from $1.85 to $2.69 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioMarin Pharmaceutical is 75.62, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 136.75.Price to Earnings Ratio vs. SectorThe P/E ratio of BioMarin Pharmaceutical is 75.62, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 212.23.Price to Earnings Growth RatioBioMarin Pharmaceutical has a PEG Ratio of 1.51. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioBioMarin Pharmaceutical has a P/B Ratio of 3.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Insiders ExposedThe Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.Click To Access This Powerful Training Right Now! About BioMarin Pharmaceutical Stock (NASDAQ:BMRN)BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.Read More BMRN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BMRN Stock News HeadlinesApril 16, 2024 | insidertrades.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Director Jean Jacques Bienaime Sells 20,000 SharesApril 13, 2024 | insidertrades.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CAO Erin Burkhart Sells 2,286 SharesApril 27, 2024 | DTI (Ad)My top 100 stocks…We recently ran an internal audit of every trade recommendation I’ve published across all my services… And let me tell ya, we found some incredible insights… For starters, we found about 100 stocks I trade really, really well.April 2, 2024 | insidertrades.comInsider Selling: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) EVP Sells 24,602 Shares of StockApril 27, 2024 | americanbankingnews.comCantor Fitzgerald Reaffirms "Overweight" Rating for BioMarin Pharmaceutical (NASDAQ:BMRN)April 27, 2024 | americanbankingnews.comBioMarin Pharmaceutical (NASDAQ:BMRN) PT Raised to $85.00April 27, 2024 | americanbankingnews.comBioMarin Pharmaceutical (NASDAQ:BMRN) PT Raised to $110.00 at Wells Fargo & CompanyApril 27, 2024 | americanbankingnews.comCitigroup Cuts BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target to $91.00April 27, 2024 | DTI (Ad)My top 100 stocks…We recently ran an internal audit of every trade recommendation I’ve published across all my services… And let me tell ya, we found some incredible insights… For starters, we found about 100 stocks I trade really, really well.April 27, 2024 | finance.yahoo.comBeyond the Balance Sheet: What SWOT Reveals About Biomarin Pharmaceutical Inc (BMRN)April 26, 2024 | msn.comToday's Stocks Selling Off: Intel, Biomarin, TextronApril 26, 2024 | markets.businessinsider.comBuy Rating Affirmed for BioMarin Pharmaceutical Amidst Strong Earnings and Voxzogo’s Growth PotentialApril 26, 2024 | finance.yahoo.comBioMarin Pharmaceutical First Quarter 2024 Earnings: EPS Beats ExpectationsApril 25, 2024 | finanznachrichten.deBioMarin Pharmaceutical Inc.: BioMarin Reports Record Financial Results for the First Quarter 2024April 25, 2024 | markets.businessinsider.comScotiabank Reaffirms Their Hold Rating on BioMarin Pharmaceutical (BMRN)April 25, 2024 | finance.yahoo.comQ1 2024 Biomarin Pharmaceutical Inc Earnings CallApril 25, 2024 | investorplace.com3 Biotech Stocks That Could Be Multibaggers in the Making: April EditionApril 25, 2024 | finance.yahoo.comBiomarin Pharmaceutical Inc (BMRN) Q1 2024 Earnings Call Transcript Highlights: Strong Growth ...April 25, 2024 | americanbankingnews.comBioMarin Pharmaceutical Sees Unusually High Options Volume (NASDAQ:BMRN)April 24, 2024 | investing.comUBS maintains Buy on BioMarin, sees Voxzogo potentialApril 24, 2024 | finance.yahoo.comBioMarin Reports Record Financial Results for the First Quarter 2024April 24, 2024 | msn.comBMRN Stock Earnings: Biomarin Pharmaceutical Beats EPS, Misses Revenue for Q1 2024April 24, 2024 | seekingalpha.comBioMarin Pharmaceutical Inc. 2024 Q1 - Results - Earnings Call PresentationApril 24, 2024 | markets.businessinsider.comBiomarin Pharmaceutical Inc. Q1 Profit Increases, beats estimatesApril 24, 2024 | sfgate.comBioMarin: Q1 Earnings SnapshotApril 24, 2024 | finance.yahoo.comBioMarin Pharmaceutical Inc. (BMRN) Q1 2024 Earnings: Surpasses Revenue and EPS EstimatesApril 24, 2024 | markets.businessinsider.comBuy Rating Affirmed on BioMarin Amid Voxzogo Success and Promising Growth OutlookSee More Headlines Receive BMRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioMarin Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today4/27/2024Next Earnings (Estimated)7/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BMRN CUSIP09061G10 CIK1048477 Webwww.bmrn.com Phone(415) 506-6700Fax415-382-7889Employees3,401Year Founded1997Price Target and Rating Average Stock Price Target$107.50 High Stock Price Target$185.00 Low Stock Price Target$78.00 Potential Upside/Downside+32.9%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage19 Analysts Profitability EPS (Most Recent Fiscal Year)$1.07 Trailing P/E Ratio75.62 Forward P/E Ratio43.74 P/E Growth1.51Net Income$167.65 million Net Margins8.31% Pretax Margin7.79% Return on Equity5.39% Return on Assets3.91% Debt Debt-to-Equity Ratio0.12 Current Ratio2.51 Quick Ratio1.57 Sales & Book Value Annual Sales$2.42 billion Price / Sales6.31 Cash Flow$1.76 per share Price / Cash Flow45.93 Book Value$26.29 per share Price / Book3.08Miscellaneous Outstanding Shares188,730,000Free Float185,261,000Market Cap$15.27 billion OptionableOptionable Beta0.31 Social Links 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Alexander Hardy (Age 55)President, CEO & Director Comp: $1.72MMr. Brian R. Mueller (Age 50)CFO & Executive VP Comp: $1.07MDr. C. Greg Guyer Ph.D. (Age 62)Executive VP & Chief Technical Officer Comp: $1.11MMr. Jeffrey Robert Ajer (Age 62)Executive VP & Chief Commercial Officer Comp: $1.1MDr. Henry J. Fuchs M.D. (Age 66)Ph.D., President of Worldwide Research & Development Comp: $1.41MMs. Erin Burkhart (Age 45)Group VP & Chief Accounting Officer Dr. Kevin Eggan Ph.D.Chief Scientific Officer & Senior VP of Research and Early DevelopmentTraci McCartyGroup Vice President of Investor RelationsMr. George Eric Davis (Age 53)Executive VP, Chief Legal Officer, General Counsel & Secretary Comp: $1.23MMs. Humaira SerajuddinSenior VP & Chief Marketing OfficerMore ExecutivesKey CompetitorsAlnylam PharmaceuticalsNASDAQ:ALNYMyoKardiaNASDAQ:MYOKUnited TherapeuticsNASDAQ:UTHRReata PharmaceuticalsNASDAQ:RETAIonis PharmaceuticalsNASDAQ:IONSView All CompetitorsInsiders & InstitutionsYousif Capital Management LLCBought 198 shares on 4/26/2024Ownership: 0.001%Fjarde AP Fonden Fourth Swedish National Pension FundBought 2,300 shares on 4/25/2024Ownership: 0.033%Summit Financial LLCSold 931 shares on 4/25/2024Ownership: 0.031%Assenagon Asset Management S.A.Sold 13,842 shares on 4/24/2024Ownership: 0.002%Simplicity Wealth LLCBought 2,958 shares on 4/24/2024Ownership: 0.002%View All Insider TransactionsView All Institutional Transactions BMRN Stock Analysis - Frequently Asked Questions Should I buy or sell BioMarin Pharmaceutical stock right now? 19 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last twelve months. There are currently 7 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BMRN shares. View BMRN analyst ratings or view top-rated stocks. What is BioMarin Pharmaceutical's stock price target for 2024? 19 brokerages have issued 12 month price objectives for BioMarin Pharmaceutical's stock. Their BMRN share price targets range from $78.00 to $185.00. On average, they predict the company's share price to reach $107.50 in the next year. This suggests a possible upside of 32.9% from the stock's current price. View analysts price targets for BMRN or view top-rated stocks among Wall Street analysts. How have BMRN shares performed in 2024? BioMarin Pharmaceutical's stock was trading at $96.42 at the beginning of the year. Since then, BMRN shares have decreased by 16.1% and is now trading at $80.91. View the best growth stocks for 2024 here. Are investors shorting BioMarin Pharmaceutical? BioMarin Pharmaceutical saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 3,690,000 shares, an increase of 20.6% from the March 31st total of 3,060,000 shares. Based on an average daily volume of 1,410,000 shares, the short-interest ratio is currently 2.6 days. View BioMarin Pharmaceutical's Short Interest. When is BioMarin Pharmaceutical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, July 29th 2024. View our BMRN earnings forecast. How were BioMarin Pharmaceutical's earnings last quarter? BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced its earnings results on Thursday, February, 22nd. The biotechnology company reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.45 by $0.05. The biotechnology company earned $646.21 million during the quarter, compared to analyst estimates of $639.53 million. BioMarin Pharmaceutical had a trailing twelve-month return on equity of 5.39% and a net margin of 8.31%. The company's quarterly revenue was up 20.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.11 EPS. What ETFs hold BioMarin Pharmaceutical's stock? ETFs with the largest weight of BioMarin Pharmaceutical (NASDAQ:BMRN) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE), Global X Genomics & Biotechnology ETF (GNOM), Simplify Health Care ETF (PINK), First Trust NYSE Arca Biotechnology Index Fund (FBT), Goldman Sachs Future Health Care Equity ETF (GDOC), VanEck Biotech ETF (BBH), Motley Fool Mid-Cap Growth ETF (TMFM) and First Trust Innovation Leaders ETF (ILDR). What guidance has BioMarin Pharmaceutical issued on next quarter's earnings? BioMarin Pharmaceutical issued an update on its FY 2024 earnings guidance on Wednesday, April, 24th. The company provided earnings per share guidance of 2.750-2.950 for the period, compared to the consensus EPS estimate of 1.650. The company issued revenue guidance of $2.7 billion-$2.8 billion, compared to the consensus revenue estimate of $2.8 billion. What is Jean-Jacques Bienaimé's approval rating as BioMarin Pharmaceutical's CEO? 228 employees have rated BioMarin Pharmaceutical Chief Executive Officer Jean-Jacques Bienaimé on Glassdoor.com. Jean-Jacques Bienaimé has an approval rating of 94% among the company's employees. This puts Jean-Jacques Bienaimé in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at BioMarin Pharmaceutical to a friend. What other stocks do shareholders of BioMarin Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), (MDVN) (MDVN), Incyte (INCY), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), Vertex Pharmaceuticals (VRTX), (KITE) (KITE) and Freeport-McMoRan (FCX). Who are BioMarin Pharmaceutical's major shareholders? BioMarin Pharmaceutical's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (0.25%), AMI Asset Management Corp (0.18%), Allspring Global Investments Holdings LLC (0.05%), Fjarde AP Fonden Fourth Swedish National Pension Fund (0.03%), Summit Financial LLC (0.03%) and IFM Investors Pty Ltd (0.02%). Insiders that own company stock include Brian Mueller, Charles Greg Guyer, Dennis Slamon, Erin Burkhart, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Mark J Alles, Richard A Meier and V Bryan Lawlis. View institutional ownership trends. How do I buy shares of BioMarin Pharmaceutical? Shares of BMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BMRN) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressJeff Bezos Just Humiliated Elon MuskInvestorPlace4 Cryptos BETTER than BitcoinTrue Market InsidersThe World's First "$20 Trillion Drug?"Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioMarin Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.